Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults. It causes progressive muscle wasting and weakness, but unlike most muscular dystrophies, it doesn’t stop at the muscles. DM1 affects the heart, eyes, hormonal system, and brain, making it a true multisystem disease.
The Genetic Cause
DM1 is caused by a specific type of mutation in the DMPK gene on chromosome 19. Inside this gene, a short segment of DNA (the letters C, T, and G) normally repeats a small number of times. In people with DM1, that segment repeats far more than it should, sometimes hundreds or even thousands of times. This is called a trinucleotide repeat expansion.
The oversized repeat doesn’t just break the gene’s protein. It produces a defective version of the molecular blueprint (messenger RNA) that gets stuck inside cells, trapping important proteins into clumps. Those clumps then interfere with how cells process instructions for many other proteins throughout the body. This cascade is why DM1 reaches so far beyond muscle tissue.
Inheritance and Anticipation
DM1 follows an autosomal dominant pattern, meaning you only need one copy of the mutated gene to develop the disease. If one parent has DM1, each child has a 50% chance of inheriting the mutation. Most people diagnosed with DM1 have a parent who also carries it, though in milder cases the parent may not have been diagnosed.
A particularly important feature of DM1 is a phenomenon called genetic anticipation. When the gene is passed from parent to child, the unstable repeat segment tends to grow longer. Longer repeats generally mean earlier onset and more severe symptoms. This means each successive generation in a family can be hit harder than the last. A grandparent might have mild grip stiffness in middle age, their child could develop noticeable weakness in their 30s, and a grandchild could be born with the congenital form of the disease.
How DM1 Affects the Muscles
The hallmark symptom is myotonia: the inability to relax a muscle after contracting it. Someone with DM1 might grip a doorknob and find their hand won’t let go, or their jaw might temporarily lock. Speech can become slurred because the muscles of the mouth and tongue are slow to release.
Muscle weakness in DM1 targets distal muscles first, the ones farthest from the center of the body. The lower legs, hands, neck, and face are typically affected earliest. This pattern creates some recognizable problems: difficulty with fine motor tasks, foot drop that changes the way a person walks, and a thinning, sharpened appearance of the face as the facial muscles waste. Over time, weakness progresses and can involve larger muscle groups closer to the trunk.
Effects Beyond the Muscles
Heart
Cardiac complications are the second leading cause of death in DM1, after respiratory failure. Roughly 80% of people with DM1 develop electrical abnormalities in the heart. The disease disrupts the conduction system, the wiring that coordinates each heartbeat. The most common problems include first-degree heart block (a delay in signals between the upper and lower chambers), bundle branch blocks, and atrial fibrillation. Even people with DM1 who feel no cardiac symptoms often show abnormal electrical patterns on an ECG.
These conduction defects tend to worsen over time. What starts as a mild delay can progress to complete heart block or dangerous arrhythmias, significantly raising the risk of sudden cardiac death. This is why regular heart monitoring, typically with an ECG every one to two years, is a core part of DM1 care. Anyone with DM1 who shows signs of cardiac involvement or is over 40 should be evaluated by a cardiologist experienced with the condition.
Eyes
Cataracts are extremely common in DM1, often developing earlier in life than typical age-related cataracts. The characteristic pattern is a specific type of lens clouding that an eye doctor may recognize as suggestive of myotonic dystrophy, sometimes even before other symptoms become obvious.
Hormones and Metabolism
A significant proportion of people with DM1 develop type 2 diabetes. The underlying cause is tied directly to the disease’s RNA problem: the molecular disruption favors a version of the insulin receptor that responds poorly to insulin, leading to insulin resistance. This isn’t the same pathway as typical type 2 diabetes, but the end result, elevated blood sugar, looks similar and requires similar management.
Brain and Sleep
DM1 can affect cognition, particularly in people who develop the disease in childhood or are born with it. Excessive daytime sleepiness is one of the most common and bothersome non-muscular symptoms, affecting quality of life even when muscle weakness is still mild. Some people also experience apathy and difficulty with executive function, which can be mistaken for depression or lack of motivation.
The Congenital Form
The most severe version of DM1 is present at birth. Congenital myotonic dystrophy occurs almost exclusively when the mutation is inherited from the mother, because the repeat expansion tends to grow dramatically during maternal transmission. Affected newborns typically have severe hypotonia (extreme floppiness), difficulty breathing, and trouble feeding. Developmental delays and cognitive impairment are common, and many of these children require intensive support from birth. The congenital form carries significant mortality in infancy, primarily from respiratory failure.
How DM1 Is Diagnosed
Genetic testing is the gold standard. A combination of two lab techniques, polymerase chain reaction and Southern blot analysis, can measure the number of CTG repeats in the DMPK gene with near-perfect accuracy. Since the repeat expansion accounts for over 99% of DM1 cases, a negative genetic test essentially rules the condition out. A blood sample is all that’s needed.
Before genetic testing became widely available, doctors relied on electromyography (EMG), which can detect the characteristic electrical pattern of myotonia in muscles. EMG is still sometimes the first clue when DM1 is suspected during a workup for unexplained muscle stiffness or weakness, but the genetic test is what confirms the diagnosis.
Management and Daily Life
There is no cure for DM1, and no treatment that slows the underlying genetic process. Management focuses on monitoring the organs at risk and treating symptoms as they arise.
For myotonia that interferes with daily activities, a medication called mexiletine can reduce muscle stiffness. However, it’s contraindicated in anyone with cardiac involvement, which is a significant limitation given how common heart problems are in DM1. Other options exist, but managing myotonia often involves balancing cardiac safety against muscle symptom relief.
Cardiac monitoring is arguably the most important piece of ongoing care. Regular ECGs, and referral to a cardiologist when abnormalities appear, can catch dangerous conduction defects before they cause a crisis. Some patients eventually need a pacemaker or implantable defibrillator. Respiratory function also needs periodic assessment, since weakness of the breathing muscles can lead to inadequate ventilation, especially during sleep. Eye exams to track cataracts, blood sugar monitoring for diabetes, and screening for sleep disorders round out the typical surveillance plan.
Physical therapy and occupational therapy play practical roles: ankle braces can compensate for foot drop, hand exercises may help maintain grip function, and respiratory therapy can support breathing muscle endurance. Many people with DM1 benefit from coordinated care at a neuromuscular center where specialists familiar with the disease can manage all its dimensions together, rather than seeing each problem in isolation.
Life Expectancy and Prognosis
DM1 is progressive, meaning it gets worse over time, but the pace varies enormously depending on when symptoms begin and how many repeats a person carries. People with mild, late-onset forms may live into their 70s with relatively modest disability. Those with the classic adult-onset form, appearing in the 20s or 30s, often experience significant disability by middle age and have a shortened life expectancy, primarily due to respiratory failure or sudden cardiac events. The congenital form carries the most serious prognosis, with the highest risks concentrated in the first year of life.
The two leading causes of death across all forms are respiratory complications and cardiac arrhythmias. Both are treatable when caught early, which is why proactive monitoring matters so much. DM1 is not a disease where you can simply treat the obvious symptoms and call it managed. It requires watching for problems that may develop silently in the heart and lungs long before a person feels them.